Condition :   Chronic Lymphocytic Leukemia

A study to assess the real-life management and use of healthcare resources during the initiation of

  • Venetoclax in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
  • Venetoclax in participants with CLL with the deletion of the short arm of chromosome 17 (del[17p]) who have received at least 1 prior therapy or participants with CLL without del (17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.

Recruitment Status: Recruiting

Condition :   Maladie de Crohn

This is a multi-center study that explores the relationship between recapture of response with escalation to weekly adalimumab and trough adalimumab concentration before escalation in patients experiencing lack of response (LOR).

Recruitment Status: Recruiting

Condition :   Hidradénite suppurée

The SOLACE study will help us generate and advance scientific knowledge of real-life management of hidradenitis suppurativa and the condition’s burden on people with moderate to severe HS.

Recruitment Status: Recruiting

Condition :   Parkinson’s Disease

The Cadence study will help us assess the impact of treatment with DUODOPA on Canadian patients with advanced Parkinson’s disease (PD).

Duodopa is the commercial name for a levodopa/carbidopa combination that comes in gel form. It is delivered inside the upper intestine via a small tube inserted directly into the first part of the small bowel, or duodenum. This unique delivery system – called intraduodenal infusion – uses a programmable pump to let the physician and patient individually tune the delivery of active ingredients, suspended as a stable gel, from a cassette worn outside the body.

Recruitment Status: Recruiting


Subscribe to Observational